IVVD vs MRNA
IVVD: Invivyd is a clinical-stage biopharma company developing monoclonal antibody therapies designed to provide continuous protection against evolving viral threats like COVID-19, RSV, and measles. MRNA: Moderna is a pioneer in mRNA technology, working to transform medicine by developing a broad pipeline of prophylactic vaccines and therapeutic medicines.
Side-by-side fundamentals
| Metric | IVVD | MRNA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $0.7004 | $197.00 | |
| Market cap | $206M | $78.6B | |
| Net margin FY2025, SEC XBRL | -98.2% | -145.2% | IVVD higher |
| Operating margin FY2025, SEC XBRL | -104.0% | -158.1% | IVVD higher |
| ROE FY2025, SEC XBRL | -21.7% | -32.6% | IVVD higher |
| ROA FY2025, SEC XBRL | -19.0% | -22.9% | IVVD higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.09 | IVVD lower |
| Revenue growth (YoY) as of 2026-09-02 | +52.3% | -27.6% | IVVD higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -53.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.63 | 1.39 | |
| 1-year return as of 2026-10-08 close | -57.3% | +605.6% | MRNA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.